# Phascolarctobacterium faecium reduces food intake via PYY signaling, contributing to the mitigation of body weight gain in diet-induced obese mice

**Authors:** Clara Bullich-Vilarrubias, Marina Romaní-Pérez, Inmaculada López-Almela, Carlos Pomares-Díaz, Silvia Basili Franzin, Giuseppe Esposito, Alfonso Benítez-Páez, Verónica Tolosa-Enguís, Yolanda Sanz

PMC · DOI: 10.1080/19490976.2026.2617691 · Gut Microbes · 2026-01-21

## TL;DR

A gut bacterium called Phascolarctobacterium faecium helps reduce food intake and body weight in obese mice through a hormone called PYY.

## Contribution

The study reveals how P. faecium mitigates obesity via PYY signaling and gut microbiota modulation in a mouse model.

## Key findings

- P. faecium reduces food intake by increasing early PYY hormone production in diet-induced obese mice.
- The bacterium modifies gut microbiota and increases branched-chain amino acids, which stimulate PYY secretion.
- P. faecium also accelerates gut transit and lipid clearance, reducing adiposity independently of food intake.

## Abstract

Excess energy intake contributes to adiposity in obesity. We investigated whether the human intestinal bacterium Phascolarctobacterium faecium could prevent obesity via enteroendocrine pathways in a mouse model of diet-induced obesity (DIO). Daily administration of P. faecium (2 × 109 cells/mouse) reduced food intake through the early overproduction of the satiety hormone peptide YY (PYY) compared to untreated DIO mice. Moreover, P. faecium increased the intestinal levels of branched-chain amino acids, which, in turn, stimulated PYY secretion in neuroendocrine cell cultures and also modified gut microbiota composition. A pair-feeding study demonstrated that the anorexigenic effect of P. faecium contributes to its effects in attenuating body weight gain in DIO mice, but that other mechanisms are also involved in its metabolic benefits. Specifically, P. faecium accelerated gut transit and serum lipid clearance, thereby limiting adiposity independently of food intake. This study identifies the mode of action of a human intestinal bacterium recently linked to obesity protection, providing valuable insights into host-microbe interactions governing body weight.

## Linked entities

- **Proteins:** PYY (peptide YY)
- **Chemicals:** branched-chain amino acids (PubChem CID 9886134)
- **Diseases:** obesity (MONDO:0011122)
- **Species:** Phascolarctobacterium faecium (taxon 33025), Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Cck (cholecystokinin) [NCBI Gene 12424], Gcg (glucagon) [NCBI Gene 14526] {aka GLP-1, Glu, PPG}, Cartpt (CART prepropeptide) [NCBI Gene 27220] {aka Cart}, Agrp (agouti related neuropeptide) [NCBI Gene 11604] {aka Agrt, Art}, Lep (leptin) [NCBI Gene 16846] {aka ob, obese}, Pomc (pro-opiomelanocortin-alpha) [NCBI Gene 18976] {aka ACTH, BE, Beta-LPH, Clip, Gamma-LPH, Npp}, Clpb (ClpB caseinolytic peptidase B) [NCBI Gene 20480] {aka Skd3}, Tlr2 (toll-like receptor 2) [NCBI Gene 24088] {aka Ly105}, Rpl19 (ribosomal protein L19) [NCBI Gene 19921], Neurod1 (neurogenic differentiation 1) [NCBI Gene 18012] {aka BETA2, BHF-1, Nd1, Neurod, bHLHa3}, Gfap (glial fibrillary acidic protein) [NCBI Gene 14580], Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, Npy (neuropeptide Y) [NCBI Gene 109648] {aka 0710005A05Rik}, Cs (citrate synthase) [NCBI Gene 12974] {aka 2610511A05Rik, 9030605P22Rik, Ahl4, Cis}, Prph (peripherin) [NCBI Gene 19132] {aka Prph1}, Neurog3 (neurogenin 3) [NCBI Gene 11925] {aka Atoh5, Math4B, bHLHa7, ngn3}, Pyy (peptide YY) [NCBI Gene 217212], Nr3c2 (nuclear receptor subfamily 3, group C, member 2) [NCBI Gene 110784] {aka MR, Mlr}
- **Diseases:** CMMP (MESH:C537394), chronic kidney disease (MESH:D051436), EECs (MESH:D002292), adiposity (MESH:D018205), dislocation (MESH:D004204), weight gain (MESH:D015430), dyslipidemia (MESH:D050171), insulin resistance (MESH:D007333), glucose intolerance (MESH:D018149), HFHSD (MESH:D008228), weight (MESH:D015431), overweight (MESH:D050177), type 2 diabetes (MESH:D003924), CD (MESH:C536209), Bw loss (MESH:D001835), hyperphagia (MESH:D006963), DIO (MESH:D009765), aggression (MESH:D010554), hyperglycemia (MESH:D006943)
- **Chemicals:** paraffin (MESH:D010232), CO2 (MESH:D002245), 2-mono-oleoylglycerol (MESH:C505247), berberine (MESH:D001599), oleic acid (MESH:D019301), BA (MESH:D001647), hematoxylin (MESH:D006416), forskolin (MESH:D005576), Cholesterol (MESH:D002784), amphotericin B (MESH:D000666), TGs (MESH:C026285), Blood glucose (MESH:D001786), SYBR Green I (MESH:C098022), Triglyceride (MESH:D014280), isoflurane (MESH:D007530), methylcellulose (MESH:D008747), acetate (MESH:D000085), penicillin (MESH:D010406), Ile (MESH:D007532), Triton X-100 (MESH:D017830), appetite-regulating hormones (MESH:D054439), propidium iodide (MESH:D011419), streptomycin (MESH:D013307), EDTA (MESH:D004492), taurine (MESH:D013654), Intralipid (MESH:C545823), eosin (MESH:D004801), glycerol (MESH:D005990), sodium taurocholate (MESH:D013656), TG (MESH:D013866), simple sugars (MESH:D009005), succinate (MESH:D019802), sucrose (MESH:D013395), CHO (MESH:C034482), ABP (MESH:C072526), BODIPY  FL C16 (MESH:C543305), metformin (MESH:D008687), AccQ-Tag (-), alpha-muricholic acid (MESH:C004821), cysteine (MESH:D003545), SCFAs (MESH:D005232), fat (MESH:D005223), Free Fatty Acid (MESH:D005230), heptanoate (MESH:D006537), branched-chain amino acids (MESH:D000597), fatty acid (MESH:D005227), Alexa Fluor 488 (MESH:C000711379), Lipid (MESH:D008055), butyrate (MESH:D002087), Val (MESH:D014633), formaldehyde (MESH:D005557), 3-isobutyl-1-methylxanthine (MESH:D015056), Leu (MESH:D007930), sugar (MESH:D000073893), glucose (MESH:D005947), PYY3-36 (MESH:C061785), propionate (MESH:D011422)
- **Species:** Homo sapiens (human, species) [taxon 9606], Akkermansia muciniphila (species) [taxon 239935], Lactobacillus (genus) [taxon 1578], Escherichia coli (E. coli, species) [taxon 562], Rattus norvegicus (brown rat, species) [taxon 10116], Mus musculus (house mouse, species) [taxon 10090], Phascolarctobacterium faecium (species) [taxon 33025], Bacteria Latreille et al. 1825 (Bacteria stick insect, genus) [taxon 629395]
- **Mutations:** D12450K
- **Cell lines:** Caco-2 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0025), SCT-1 — Silurus meridionalis (Southern catfish), Spontaneously immortalized cell line (CVCL_YL76), CMMP — Rattus norvegicus (Rat), Transformed cell line (CVCL_4285), STC-1 — Homo sapiens (Human), Lung small cell carcinoma, Cancer cell line (CVCL_3171)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12834159/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12834159/full.md

## References

93 references — full list in the complete paper: https://tomesphere.com/paper/PMC12834159/full.md

---
Source: https://tomesphere.com/paper/PMC12834159